Although the FSH receptor has been studied before in other malignancies, including prostate, breast, colon, pancreas, urinary bladder, lung and testis carcinomas, in order to further develop theranostics focusing on ovarian tumors, a review on the expression of the FSH receptor specifically in ovarian tumors was performed [12,13,15,16]. The gene discussed is FSHR; the disease is ovarian neoplasm.